Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 2.99
MDVN's Cash to Debt is ranked lower than
67% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. MDVN: 2.99 )
Ranked among companies with meaningful Cash to Debt only.
MDVN' s 10-Year Cash to Debt Range
Min: 1.1  Med: 9999.00 Max: No Debt
Current: 2.99
Equity to Asset 0.57
MDVN's Equity to Asset is ranked lower than
63% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. MDVN: 0.57 )
Ranked among companies with meaningful Equity to Asset only.
MDVN' s 10-Year Equity to Asset Range
Min: -0.02  Med: 0.45 Max: 0.99
Current: 0.57
-0.02
0.99
Interest Coverage 12.99
MDVN's Interest Coverage is ranked lower than
90% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MDVN: 12.99 )
Ranked among companies with meaningful Interest Coverage only.
MDVN' s 10-Year Interest Coverage Range
Min: 12.99  Med: 10000.00 Max: 9999.99
Current: 12.99
12.99
9999.99
F-Score: 5
Z-Score: 13.06
M-Score: -0.50
WACC vs ROIC
6.71%
183.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 37.12
MDVN's Operating margin (%) is ranked higher than
94% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. MDVN: 37.12 )
Ranked among companies with meaningful Operating margin (%) only.
MDVN' s 10-Year Operating margin (%) Range
Min: -510.27  Med: -62.99 Max: 66.67
Current: 37.12
-510.27
66.67
Net-margin (%) 33.96
MDVN's Net-margin (%) is ranked higher than
93% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. MDVN: 33.96 )
Ranked among companies with meaningful Net-margin (%) only.
MDVN' s 10-Year Net-margin (%) Range
Min: -496.58  Med: -54.45 Max: 38.91
Current: 33.96
-496.58
38.91
ROE (%) 71.97
MDVN's ROE (%) is ranked higher than
98% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. MDVN: 71.97 )
Ranked among companies with meaningful ROE (%) only.
MDVN' s 10-Year ROE (%) Range
Min: -862.65  Med: -53.26 Max: 105.07
Current: 71.97
-862.65
105.07
ROA (%) 34.24
MDVN's ROA (%) is ranked higher than
98% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. MDVN: 34.24 )
Ranked among companies with meaningful ROA (%) only.
MDVN' s 10-Year ROA (%) Range
Min: -80.48  Med: -12.69 Max: 42.39
Current: 34.24
-80.48
42.39
ROC (Joel Greenblatt) (%) 228.19
MDVN's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. MDVN: 228.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MDVN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -201825  Med: -4226.22 Max: 299.98
Current: 228.19
-201825
299.98
Revenue Growth (3Y)(%) 113.40
MDVN's Revenue Growth (3Y)(%) is ranked higher than
97% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. MDVN: 113.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MDVN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -100.00 Max: 113.4
Current: 113.4
0
113.4
» MDVN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

MDVN Guru Trades in Q3 2014

John Burbank 2,451 sh (New)
Jim Simons 108,728 sh (New)
Paul Tudor Jones 11,585 sh (New)
Joel Greenblatt 13,970 sh (New)
Mario Gabelli Sold Out
» More
Q4 2014

MDVN Guru Trades in Q4 2014

Steven Cohen 24,200 sh (New)
Ken Fisher 2,532 sh (New)
Jim Simons 257,100 sh (+136.46%)
Joel Greenblatt 31,518 sh (+125.61%)
John Burbank Sold Out
Paul Tudor Jones 5,919 sh (-48.91%)
» More
Q1 2015

MDVN Guru Trades in Q1 2015

Louis Moore Bacon 15,000 sh (New)
Joel Greenblatt 150,526 sh (+377.59%)
Jim Simons 434,231 sh (+68.90%)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Ken Fisher 2,400 sh (-5.21%)
» More
Q2 2015

MDVN Guru Trades in Q2 2015

Steven Cohen 98,700 sh (New)
Jim Simons 795,100 sh (+83.11%)
Joel Greenblatt 250,394 sh (+66.35%)
Ken Fisher 2,400 sh (unchged)
Louis Moore Bacon Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MDVN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 30.30
MDVN's P/E(ttm) is ranked higher than
54% of the 220 Companies
in the Global Biotechnology industry.

( Industry Median: 33.70 vs. MDVN: 30.30 )
Ranked among companies with meaningful P/E(ttm) only.
MDVN' s 10-Year P/E(ttm) Range
Min: 30.27  Med: 40.43 Max: 329.46
Current: 30.3
30.27
329.46
Forward P/E 20.45
MDVN's Forward P/E is ranked higher than
56% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 23.42 vs. MDVN: 20.45 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 30.30
MDVN's PE(NRI) is ranked higher than
54% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 33.30 vs. MDVN: 30.30 )
Ranked among companies with meaningful PE(NRI) only.
MDVN' s 10-Year PE(NRI) Range
Min: 30.26  Med: 40.42 Max: 325.93
Current: 30.3
30.26
325.93
P/B 13.32
MDVN's P/B is ranked lower than
87% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. MDVN: 13.32 )
Ranked among companies with meaningful P/B only.
MDVN' s 10-Year P/B Range
Min: 0.7  Med: 36.11 Max: 1848.25
Current: 13.32
0.7
1848.25
P/S 9.65
MDVN's P/S is ranked higher than
50% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. MDVN: 9.65 )
Ranked among companies with meaningful P/S only.
MDVN' s 10-Year P/S Range
Min: 4.54  Med: 24.17 Max: 563.33
Current: 9.65
4.54
563.33
PFCF 33.48
MDVN's PFCF is ranked higher than
56% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 40.25 vs. MDVN: 33.48 )
Ranked among companies with meaningful PFCF only.
MDVN' s 10-Year PFCF Range
Min: 3.04  Med: 40.41 Max: 253.5
Current: 33.48
3.04
253.5
POCF 31.79
MDVN's POCF is ranked lower than
52% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 32.50 vs. MDVN: 31.79 )
Ranked among companies with meaningful POCF only.
MDVN' s 10-Year POCF Range
Min: 3.03  Med: 38.82 Max: 202.8
Current: 31.79
3.03
202.8
EV-to-EBIT 24.34
MDVN's EV-to-EBIT is ranked higher than
52% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 26.88 vs. MDVN: 24.34 )
Ranked among companies with meaningful EV-to-EBIT only.
MDVN' s 10-Year EV-to-EBIT Range
Min: -658.8  Med: -26.20 Max: 156.7
Current: 24.34
-658.8
156.7
Shiller P/E 1285.45
MDVN's Shiller P/E is ranked lower than
96% of the 112 Companies
in the Global Biotechnology industry.

( Industry Median: 44.71 vs. MDVN: 1285.45 )
Ranked among companies with meaningful Shiller P/E only.
MDVN' s 10-Year Shiller P/E Range
Min: 1258  Med: 1515.29 Max: 1686.29
Current: 1285.45
1258
1686.29
Current Ratio 2.60
MDVN's Current Ratio is ranked lower than
67% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. MDVN: 2.60 )
Ranked among companies with meaningful Current Ratio only.
MDVN' s 10-Year Current Ratio Range
Min: 1.46  Med: 3.87 Max: 27.3
Current: 2.6
1.46
27.3
Quick Ratio 2.60
MDVN's Quick Ratio is ranked lower than
63% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. MDVN: 2.60 )
Ranked among companies with meaningful Quick Ratio only.
MDVN' s 10-Year Quick Ratio Range
Min: 1.46  Med: 3.87 Max: 27.3
Current: 2.6
1.46
27.3
Days Sales Outstanding 92.25
MDVN's Days Sales Outstanding is ranked lower than
68% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. MDVN: 92.25 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDVN' s 10-Year Days Sales Outstanding Range
Min: 34.21  Med: 94.91 Max: 143.37
Current: 92.25
34.21
143.37

Valuation & Return

vs
industry
vs
history
Price/Net Cash 74.63
MDVN's Price/Net Cash is ranked lower than
96% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. MDVN: 74.63 )
Ranked among companies with meaningful Price/Net Cash only.
MDVN' s 10-Year Price/Net Cash Range
Min: 3  Med: 18.07 Max: 191.56
Current: 74.63
3
191.56
Price/Net Current Asset Value 21.96
MDVN's Price/Net Current Asset Value is ranked lower than
86% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. MDVN: 21.96 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MDVN' s 10-Year Price/Net Current Asset Value Range
Min: 2.88  Med: 32.78 Max: 364.25
Current: 21.96
2.88
364.25
Price/Tangible Book 16.87
MDVN's Price/Tangible Book is ranked lower than
86% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. MDVN: 16.87 )
Ranked among companies with meaningful Price/Tangible Book only.
MDVN' s 10-Year Price/Tangible Book Range
Min: 0.3  Med: 14.78 Max: 1152.75
Current: 16.87
0.3
1152.75
Price/Projected FCF 17.40
MDVN's Price/Projected FCF is ranked lower than
83% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. MDVN: 17.40 )
Ranked among companies with meaningful Price/Projected FCF only.
MDVN' s 10-Year Price/Projected FCF Range
Min: 1.92  Med: 9.84 Max: 240
Current: 17.4
1.92
240
Price/Median PS Value 0.40
MDVN's Price/Median PS Value is ranked higher than
88% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. MDVN: 0.40 )
Ranked among companies with meaningful Price/Median PS Value only.
MDVN' s 10-Year Price/Median PS Value Range
Min: 0.18  Med: 0.68 Max: 2.87
Current: 0.4
0.18
2.87
Price/Graham Number 4.46
MDVN's Price/Graham Number is ranked lower than
68% of the 173 Companies
in the Global Biotechnology industry.

( Industry Median: 3.26 vs. MDVN: 4.46 )
Ranked among companies with meaningful Price/Graham Number only.
MDVN' s 10-Year Price/Graham Number Range
Min: 5.36  Med: 6.66 Max: 21.35
Current: 4.46
5.36
21.35
Earnings Yield (Greenblatt) (%) 4.10
MDVN's Earnings Yield (Greenblatt) (%) is ranked higher than
87% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. MDVN: 4.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDVN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.6  Med: 2.80 Max: 4.1
Current: 4.1
0.6
4.1

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 854 1,070 1,417
EPS($) 1.66 4.30 6.09
EPS without NRI($) 1.66 4.30 6.09

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:WMD.Germany,
Medivation Inc was formed in Delaware in October 1995. The Company is a biopharmaceutical company engaged in the rapid development of novel small molecule drugs to treat diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc., or Astellas, the Company is developing XTANDI enzalutamide capsules. Together with Astellas, it is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer. Based on the positive results of the AFFIRM trial, the Company has exercised its right under its collaboration agreement with Astellas to co-promote XTANDI in the U.S., should it receive marketing approval. Their subsidiaries are Medivation Prostate Therapeutics Inc or MPT, Medivation Neurology Inc or MNI, Medivation Technologies Inc, or MTI, Medivation Field Solutions, Inc., or MFSI, and Medivation Services, Inc., or MSI. MPT holds the intellectual property rights covering XTANDI. MNI holds the intellectual property rights covering dimebon, which was in development for Alzheimer's disease and Huntington disease under its former collaboration with Pfizer. MTI holds the intellectual property rights covering its early-stage technologies. MFSI provides commercialization services to the Company, and MSI provides research and development services. It has received "Fast Track" designation from the U.S. Food and Drug Administration for the post-docetaxel indication. The Company is conducting this program in collaboration with Astellas. The Company is subject to extensive regulation by the Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.
» More Articles for MDVN

Headlines

Articles On GuruFocus.com
Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talaz Aug 24 2015 
Medivation Announces Second Quarter 2015 Financial Results Teleconference on August 6, 2015 Jul 16 2015 
Medivation Voted Three Years in a Row Among Top Workplaces in the San Francisco Bay Area Jun 29 2015 
current Apr 10 2015 
Brean Capital Weighs in on Medivation Following Update on TERRAIN Study Mar 26 2015 
Wedbush Weighs in on Medivation Following Phase II TERRAIN Study Results Feb 03 2015 
Weekly CEO Sells Highlight: QAD Inc, Orbitz Worldwide Inc, Constellation Brands Inc, and Medivation Jan 25 2015 
Enzalutamide Phase 2 Terrain Trial Demonstrated Statistically Significant Increase in PFS as Compare Jan 22 2015 
William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
Medivation and Astellas Announce Phase 3 Study of Enzalutamide in Men With High-Risk, Hormone-Sensit Oct 30 2014 

More From Other Websites
Medivation, Inc. Earnings Q2, 2015 Aug 27 2015
The Zacks Analyst Blog Highlights: Vital Therapies, Amgen, BioMarin, Acorda and Macrocure Aug 27 2015
Medivation to Gain Global Rights to BioMarin's Talazoparib Aug 25 2015
BioMarin's Medivation Deal Boosts EPS Aug 25 2015
Two Bay Area drug companies cut half-billion-dollar cancer drug deal Aug 24 2015
Medivation Buying Breast-Cancer Drug From BioMarin Aug 24 2015
Medivation buying rights to BioMarin cancer drug Aug 24 2015
Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to... Aug 24 2015
Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to... Aug 24 2015
MEDIVATION, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD... Aug 24 2015
Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to... Aug 24 2015
Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to... Aug 24 2015
Why Medivation is a Stunning Biotech Opportunity Aug 21 2015
MEDIVATION, INC. Financials Aug 14 2015
10-Q for Medivation, Inc. Aug 08 2015
Medivation Tops Q2 Earnings & Ups View, Xtandi Impresses - Analyst Blog Aug 07 2015
Edited Transcript of MDVN earnings conference call or presentation 6-Aug-15 8:30pm GMT Aug 07 2015
Medivation tops Street 2Q forecasts Aug 06 2015
Medivation tops Street 2Q forecasts Aug 06 2015
Medivation Reports Second Quarter 2015 Financial Results Aug 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK